StockData
Evaxion A/S logo

Evaxion A/S (EVAX) company profile

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.74−0.03 (-1.08%)

Close on Nov 13, 2026Market cap $22.85MP/E –Yield –

About Evaxion A/S

Biological Products, (No Diagnostic Substances), SIC 2836

Evaxion is a biotechnology company that develops targeted immunotherapies and vaccines for cancers and infectious diseases using its proprietary artificial intelligence platform, AI-Immunology. The platform identifies novel disease targets and predicts immune responses to engineer therapeutic cancer vaccines and prophylactic bacterial and viral treatments. Its clinical and preclinical research programs address conditions such as melanoma, leukemia, gonorrhea, and cytomegalovirus. The company generates value through its internal pipeline assets and strategic research collaborations, serving pharmaceutical companies and healthcare partners through licensing and co-development partnerships.

The company operates its research and development activities through dedicated wet-lab and animal testing facilities, utilizing third-party contract manufacturers for trial drug supply. Evaxion maintains international collaborations, including development agreements with partner organizations across the United States, Africa, and global non-profit foundations. Founded in Denmark, the company conducts its business under Danish law and coordinates global operations from Denmark.

Summary of the business section of Evaxion A/S's latest annual report, written by StockData.

Company profile

Company

Legal name
Evaxion A/S
Founded
2008
Headquarters
Hoersholm, Denmark
Address
Dr Neergaards Vej 5f
Phone
(455) 265-6554
Website
evaxion.ai
Employees
45, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
G7
Fiscal year ends
December 31
Auditor
EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark

Stock & identifiers

Ticker
EVAX
Exchange
Nasdaq
IPO date
Feb 5, 2021
Shares outstanding
417M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-5 reverse, Jan 14, 2025; 1-for-10 reverse, Jan 22, 2024
SEC CIK
1828253
CUSIP
29970R303
ISIN
US29970R3030
FIGI
BBG00YTSS733
Share class FIGI
BBG00YTSS7Z8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Andreas Holm MattssonCAIO Chief AI Officer5,524,916
Helen Katrina Tayton-MartinChief Executive Officer2,286,150
Thomas Frederik SchmidtChief Financial Officer645,750
Birgitte RonoChief Scientific Officer36,765
A/S EvaxionChief Financial Officer1,147,178
Jens Bitsch-NorhaveDirector2,376
Marianne SoegaardDirector3,863,115
Lars Aage Staal WegnerDirector129,139
Roberto PregoDirector1,171,030
Lars HoltugDirector258,029

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 5, 2021
Offer price
$10.00
Securities offered
3,000,000
Gross proceeds
$30.00M
Exchange
Nasdaq
First trading day
Feb 5, 2021
First-day close
$9.89-1.1%
Lock-up ends (est.)
Aug 4, 2021

“The initial public offering price is $10.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 45 full-time equivalent employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 5, 2025Name changeName changed from Evaxion Biotech A/S to Evaxion A/S
Feb 5, 2021IPOInitial public offering priced (424B4 prospectus)
Jan 26, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?